Reduced serum chemerin in patients with more severe liver cirrhosis

Eisinger, Kristina; Krautbauer, Sabrina; Wiest, Reiner; Weiss, Thomas S; Buechler, Christa (2015). Reduced serum chemerin in patients with more severe liver cirrhosis. Experimental and molecular pathology, 98(2), pp. 208-213. Elsevier 10.1016/j.yexmp.2015.01.010

[img] Text
Reduced serum chemerin in patients with more severe liver cirrhosis..pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (557kB) | Request a copy

Chemerin is a well-established modulator of immune cell function and its serum levels are induced in inflammatory diseases. Liver cirrhosis is associated with inflammation which is aggravated by portal hypertension. The objective of this study was to evaluate whether chemerin is induced in patients with more severe liver cirrhosis and portal hypertension. Chemerin has been measured by ELISA in the portal venous serum (PVS), systemic venous serum (SVS) and hepatic venous serum (HVS) of 45 patients with liver cirrhosis. Chemerin is higher in HVS compared to PVS in accordance with our recently published finding. SVS, HVS and PVS chemerin decline in patients with more advanced liver injury defined by the CHILD-PUGH score. Hepatic chemerin has been determined in a small cohort and is similarly expressed in normal and cirrhotic liver. MELD score and serum markers of liver and kidney function do not correlate with chemerin. There is a positive correlation of chemerin in all compartments with Quick prothrombin time and of SVS chemerin with systolic blood pressure. PVS chemerin is induced in patients with modest/massive ascites but this does not translate into higher HVS and SVS levels. Chemerin is not associated with variceal size. Reduction of portal pressure by transjugular intrahepatic portosystemic shunt does not affect chemerin levels. These data show that low chemerin in patients with more severe liver cirrhosis is associated with reduced Quick prothrombin time.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology

UniBE Contributor:

Wiest, Reiner


600 Technology > 610 Medicine & health








Lilian Karin Smith-Wirth

Date Deposited:

04 Apr 2016 13:39

Last Modified:

09 Sep 2017 13:14

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

Adipokine; CHILD-PUGH stage; Portal hypertension; Portal vein




Actions (login required)

Edit item Edit item
Provide Feedback